ONCOPEPTIDES
Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.
ONCOPEPTIDES
Industry:
Biotechnology Clinical Trials Pharmaceutical
Founded:
2000-01-01
Address:
Stockholm, Stockholms Lan, Sweden
Country:
Sweden
Website Url:
http://www.oncopeptides.com
Total Employee:
251+
Status:
Active
Contact:
46 7 05 69 54 71
Total Funding:
209.18 M USD
Technology used in webpage:
Domain Not Resolving Global Site Tag IPv6 US Privacy User Signal Mechanism DoubleClick.Net Cloudflare SSL Amazon Virginia Region Cloudflare CDN ASP.NET 4.0 ASP.NET Ajax
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Board_member
Board_member
2018-01-01
Board_member
Board_member
Current Employees Featured
Rolf Larsson Founder @ Oncopeptides
Founder
2000-01-01
Joachim Gullbo Founder @ Oncopeptides
Founder
2000-01-01
Diego Grauman Executive Director - USMA @ Oncopeptides
Executive Director - USMA
2021-03-01
Jakob Lindberg Chief Scientific Officer, CSO @ Oncopeptides
Chief Scientific Officer, CSO
2020-06-30
Annika Muskantor CFO @ Oncopeptides
CFO
Peter Nygren Founder @ Oncopeptides
Founder
2000-01-01
Anders Martin CFO & Deputy CEO @ Oncopeptides
CFO & Deputy CEO
Founder
Stock Details
Investors List
Vinnova
Vinnova investment in Grant - Oncopeptides
Artisan Partners
Artisan Partners investment in Post-IPO Equity - Oncopeptides
Bain Capital
Bain Capital investment in Post-IPO Equity - Oncopeptides
Industrifonden
Industrifonden investment in Series A - Oncopeptides
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-01 | Oncopeptides appoints Annika Muskantor as interim CFO |
Official Site Inspections
http://www.oncopeptides.com Semrush global rank: 437.71 K Semrush visits lastest month: 121.55 K
Unable to get host informations!!!
More informations about "Oncopeptides"
Company - Oncopeptides
Start - English - Oncopeptides
Oct 11, 2024 Oncopeptides is a global biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat hematological diseases. ...See details»
Oncopeptides - Overview, News & Similar companies - ZoomInfo
Jun 5, 2023 Oncopeptides Chief Financial Officer Holger Lembrer takes office today STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a …See details»
Oncopeptides - Crunchbase Company Profile & Funding
Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides …See details»
Oncopeptides - Overview, News & Similar companies - ZoomInfo
Who is Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. T he company …See details»
Oncopeptides Company Profile - Craft
Oncopeptides has 5 employees across 5 locations and kr35.22 m in annual revenue in FY 2023. See insights on Oncopeptides including office locations, competitors, revenue, financials, …See details»
Oncopeptides withdraws Pepaxto® in US, scale down …
Oct 22, 2021 Oncopeptides is developing several new compounds based on the PDC platform. The global Headquarters is based in Stockholm, Sweden and the U.S. Headquarters is …See details»
Oncopeptides withdraws Pepaxto® in US, scale down …
Oct 22, 2021 Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announces that the company has decided to withdraw Pepaxto® (INN melphalan flufenamide) from the market in …See details»
Our history - Oncopeptides
Oncopeptides AB (publ) was formed in year 2000 by some of Sweden’s leading cancer researchers and cancer research institutions. More than 20 years later the company is …See details»
Oncopeptides - VentureRadar
Oncopeptides is targeting multiple myeloma as a first indication with its lead compound, named melflufen which is a cytosuperior of the chemotherapeutic alkylator melphalan. A family of …See details»
Oncopeptides - Contacts, Employees, Board Members, Advisors
Organization. Oncopeptides . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Contacts 51. About. Oncopeptides has 7 …See details»
Start - English - Oncopeptides Germany
Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company is science driven and is …See details»
Start - Oncopeptides ES
Oncopeptides es una empresa biotecnológica centrada en la investigación, el desarrollo y la comercialización de terapias dirigidas contra cánceres difíciles de tratar.See details»
Culture & values - Oncopeptides
Oncopeptides has a values-driven culture and an inclusive organization that welcomes people with different backgrounds and perspectives. We have five core values that serve as our …See details»
Oncopeptides strengthens its organization by appointing Linda …
Dec 15, 2020 Prior to joining Oncopeptides she held the position as Senior Corporate Communications and Investor Relations Manager at Sobi, Swedish Orphan Biovitrum AB …See details»
Start - Oncopeptides Germany
Oncopeptides ist ein Biotech-Unternehmen aus Schweden, das sich auf die Erforschung, Entwicklung und Vermarktung von zielgerichteten Therapien für schwer behandelbare …See details»
Phase 3 Randomized Study of Daratumumab Monotherapy Versus …
Nov 5, 2024 Introduction: High-risk smoldering multiple myeloma (SMM) is an asymptomatic precursor disorder to active multiple myeloma (MM) without approved treatment options. …See details»
Oncopeptalks - meet the Italian team - Oncopeptides
4 days ago You are now leaving the global website of Oncopeptides AB, Sweden. The link you clicked will take you the website of our Spanish operations at oncopeptides.es. Stay on page …See details»
Oncopeptides publishes the 2021 Annual Report
STOCKHOLM — April 21, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat …See details»
Start - Svenska - Oncopeptides
4 days ago Oncopeptides inbjudna att presentera på ASH i december. 20 november 2024. Oncopeptides meddelar idag att en utvärdering av aktiviteten hos två peptidkonjugat (PDCer) …See details»